Srishti Kushwaha,
Sonam Gupta,
Sumit Pandey,
- Student, Department of Biotechnology, Bansal Institute of Engineering and Technology, Lucknow, Uttar Pradesh, India
- Student, Department of Biotechnology, Bansal Institute of Engineering and Technology, Lucknow, Uttar Pradesh, India
- Assistant Professor, Department of Biotechnology, Bansal Institute of Engineering and Technology, Lucknow, Uttar Pradesh, India
Abstract
Alzheimer’s disease (AD) is a condition that leads to the deterioration of brain cells and is the primary cause of dementia, characterized by a decline in autonomy and cognitive function in day-to-day activities. The cholinergic hypothesis and the amyloid hypothesis are the two main theories proposed to explain AD’s multifaceted nature. Characterized by a decline in autonomy and cognitive function in day-to-day activities. The cholinergic hypothesis and the amyloid hypothesis are the two main theories proposed to explain AD’s multifaceted nature. Moreover, various risk factors, including advancing age, genetic predispositions, cranial injuries, vascular disorders, infections, and environmental influences, contribute to the disease. There are only two types of drugs that are approved to treat Alzheimer’s disease (AD) right now. These are N-methyl d-aspartate (NMDA) antagonists and cholinesterase enzyme inhibitors. These drugs only help with the symptoms of AD; they do not cure or stop the disease. Today, researchers are trying to figure out what causes Alzheimer’s disease by looking at different processes, like the metabolism of tau protein, beta-amyloid, the inflammatory response, and damage from free radicals and cholinergic neurons. They are looking for efficient therapies that can halt the illness or alter its progression. This review examines existing pharmacological interventions and prospective theories for the advancement of novel treatments for Alzheimer’s Disease (AD), including disease-modifying therapies (DMT), chaperones, and natural substances.
Keywords: Alzheimer’s disease, neurodegeneration Beta-amyloid peptide, tau protein, risk factors, disease-modifying therapy
References
[1] Alzheimer’s Association, “Alzheimer’s Disease Facts and Figures,” Alzheimer’s & Dementia Journal, 2023.
[2] World Health Organization, “Dementia: A Public Health Priority,” WHO Report, 2022.
[3] J. Hardy and D. J. Selkoe, “The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems,” Science, 2002.
[4] C. R. Jack et al., “NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease,” Alzheimer’s & Dementia, 2018.
[5] D. P. DeTure and D. W. Dickson, “The Neuropathological Diagnosis of Alzheimer’s Disease,” Molecular Neurodegeneration, 2019.
[6] R. C. Petersen et al., “Mild Cognitive Impairment: Clinical Characterization and Outcome,” Archives of Neurology, 1999.
[7] K. He et al., “Deep Learning for Alzheimer’s Disease Detection Using MRI Images,” IEEE Access, 2020.
[8] S. Basaia et al., “Automated Classification of Alzheimer’s Disease Using MRI and Deep Neural Networks,” NeuroImage: Clinical, 2019.
Research and Reviews: A Journal of Pharmacology
| Volume | 16 | |
| 03 | ||
| Received | 23/07/2026 | |
| Accepted | 05/08/2026 | |
| Published | 23/08/2026 | |
| Publication Time | 31 Days |